Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-AF: Tirzepatide After Catheter Ablation of Atrial Fibrillation
NCT07382024Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tirzepatide in Atrial fibrillation (AFib) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Atrial fibrillation burden at 3 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07382024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382024.